From "Behind-the-Scenes Driver" to "Star Target": Why Has MSLN Become a New Focus in Solid Tumor Immunotherapy? (With cellular-level EC50 and internalization verification data)
May 27, 202612 min read
Target deep-dives, project case studies, service brochures, events and offers — a closer look at SanjingBio's platforms and delivery.
Pipeline Analysis
The 114 targets in SanjingBio's pipeline broken down by indication: oncology dominates, with autoimmune and metabolic together under twenty percent. Set against three years of ADC and bispecific clinical progress, where are the non-oncology gaps?
Live demos of our nanobody discovery platform, with validation data from the complete FRα and HER2 solutions on display.
Event details ↗
Case studies of antibody epitope mapping with 300 kV cryo-EM.
Event details ↗On-site consultations on our alpaca immunization platform and stable cell line development services.
Event details ↗
20% off catalog products site-wide on your first quote order, any category. For first-time institutional customers only, capped at US$5,000 per order; just mention the promotion in your order notes when requesting a quote.
Pick any 4 recombinant protein catalog numbers in one order and the lowest-priced item is free. Limited to SJR-prefixed catalog numbers, any size, stackable with catalog pricing.
Sign a full-workflow antibody discovery contract within the validity period for 15% off plus priority scheduling. New custom development projects only.
Why an early-discovery CRO built its own cryo-EM, and what it actually solves in antibody epitope mapping.
Mar 26, 2026
Share the intended application and what you already have in hand. A scientist — not a sales rep — will scope feasibility, suggest the right route and send a quote, usually within one business day.
